Contact your GP or prescribing clinician if you experience : Severe or rapidly progressive hair loss , particularly if it occurs in patches rather than diffuse thinning Hair loss accompanied by scalp symptoms such as redness, scaling, itching, pain, or visible inflammation (which may indicate scarring alopecia requiring urgent dermatology referral) Signs of potential nutritional deficiency , including persistent fatigue, weakness, pallor, brittle nails, mouth ulcers, or neurological symptoms Hair loss persisting beyond 69 months or worsening despite nutritional optimisation Significant psychological distress related to hair changes affecting your quality of life Your healthcare provider may recommend blood tests to investigate potential underlying causes, which might include: Full blood count : To assess for anaemia Ferritin levels : To evaluate iron stores (aim to treat iron deficiency to within the laboratory reference range) Thyroid function tests : To exclude hypothyroidism or hyperthyroidism Vitamin B12 and folate : Particularly relevant if dietary intake is restricted Coeliac serology : May be considered if iron deficiency is present without obvious cause Zinc levels : Though testing can be unreliable, may be considered in specific circumstances Depending on findings, your GP may suggest adjusting your GLP-1 dosage , slowing the rate of weight loss, or referring you to a dermatologist for specialist assessment if hair loss appears atypical or fails to improve
Double blind, randomized, placebo or semaglutide
I want to empower the next generation of politicians and community activists and teachers and doctors and lawyers and I wantI want to be a part of laying out a set of values and principles that we can all be proud of in this country
SEE IF SEMAGLUTIDE IS RIGHT FOR YOU What Semaglutide Does (and Why Duration Matters) Semaglutide helps with weight loss by reducing appetite, slowing stomach emptying, and helping you feel full sooner
In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation
Heart health and weight-related risk Some semaglutide-containing medications are approved to reduce the risk of major heart-related events in certain adults who meet specific criteria
